David Barras
Articles
-
Nov 27, 2024 |
nature.com | Anais Elewaut |Felix Bayerl |Martin Schönlein |Trung Nguyen |Trung Nguyễn |Francesco Andreatta | +12 more
AbstractThe tumour microenvironment is programmed by cancer cells and substantially influences anti-tumour immune responses1,2. Within the tumour microenvironment, CD8+ T cells undergo full effector differentiation and acquire cytotoxic anti-tumour functions in specialized niches3,4,5,6,7. Although interactions with type 1 conventional dendritic cells have been implicated in this process3,4,5,8,9,10, the underlying cellular players and molecular mechanisms remain incompletely understood.
-
Nov 27, 2024 |
AbstractThe tumour microenvironment is programmed by cancer cells and substantially influences anti-tumour immune responses1,2. Within the tumour microenvironment, CD8+ T cells undergo full effector differentiation and acquire cytotoxic anti-tumour functions in specialized niches3,4,5,6,7. Although interactions with type 1 conventional dendritic cells have been implicated in this process3,4,5,8,9,10, the underlying cellular players and molecular mechanisms remain incompletely understood.
-
Jun 25, 2024 |
nature.com | Remy Petremand |Johanna Chiffelle |Marion Arnaud |David Barras |Maria Lozano-Rabella |Raphael Genolet | +6 more
Correction to: Nature Biotechnology https://doi.org/10.1038/s41587-024-02232-0, published online 7 May 2024In the version of the article initially published, there were errors in Extended Data Fig. 5e. One patient was erroneously omitted due to an inaccurate y-axis scale, and in the key “n = 17” has been corrected to “n = 12”. These corrections have been made to the HTML and PDF versions of the article.
-
Jun 25, 2024 |
Correction to: Nature Biotechnology https://doi.org/10.1038/s41587-024-02232-0, published online 7 May 2024In the version of the article initially published, there were errors in Extended Data Fig. 5e. One patient was erroneously omitted due to an inaccurate y-axis scale, and in the key “n = 17” has been corrected to “n = 12”. These corrections have been made to the HTML and PDF versions of the article.
-
May 7, 2024 |
nature.com | Remy Petremand |Johanna Chiffelle |Marion Arnaud |David Barras |Maria Lozano-Rabella |Raphael Genolet | +6 more
AbstractA central challenge in developing personalized cancer cell immunotherapy is the identification of tumor-reactive T cell receptors (TCRs).
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →